Provided by Tiger Trade Technology Pte. Ltd.

Dianthus Therapeutics Inc.

52.86
+0.18000.34%
Pre-market: 52.860.00000.00%08:56 EST
Volume:570.80K
Turnover:30.47M
Market Cap:2.28B
PE:-15.15
High:54.24
Open:52.87
Low:52.57
Close:52.68
52wk High:57.50
52wk Low:13.37
Shares:43.22M
Float Shares:21.08M
Volume Ratio:1.00
T/O Rate:2.71%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4892
EPS(LYR):-2.5506
ROE:-28.57%
ROA:-18.82%
PB:4.18
PE(LYR):-20.72

Loading ...

BUZZ-Dianthus Therapeutics surges again ahead of planned equity raise

Reuters
·
Sep 10, 2025

Dianthus Therapeutics Is Maintained at Outperform by Baird

Dow Jones
·
Sep 09, 2025

Dianthus Therapeutics Inc. Announces $150 Million Underwritten Public Offering to Advance Antibody Therapeutics Development

Reuters
·
Sep 09, 2025

Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering

THOMSON REUTERS
·
Sep 09, 2025

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

Dow Jones
·
Sep 08, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Sanofi SA, Nutanix, Bullish

Reuters
·
Sep 08, 2025

Dianthus Therapeutics Shares Reverse Course, Last up 19.3% After Mid-Stage Trial Data for Its Muscle-Weakening Drug

THOMSON REUTERS
·
Sep 08, 2025

Evercore ISI Adjusts Dianthus Therapeutics Price Target to $72 From $50, Maintains Outperform Rating

MT Newswires Live
·
Sep 08, 2025

Dianthus Therapeutics Shares Reverse Premarket Gains, Last Down 13.2%

THOMSON REUTERS
·
Sep 08, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Veeva, Gold miners, Ideaya Biosciences

Reuters
·
Sep 08, 2025

BUZZ-Dianthus Therapeutics rises after mid-stage trial win for muscle-weakening drug

Reuters
·
Sep 08, 2025

Dianthus Therapeutics Inc - Claseprubart Shows Favorable Safety Profile

THOMSON REUTERS
·
Sep 08, 2025

Dianthus Therapeutics Inc - Phase 3 Gmg Trial for Claseprubart Anticipated to Start in 2026

THOMSON REUTERS
·
Sep 08, 2025

Dianthus Therapeutics Inc. Announces Phase 2 MaGic Trial Results for Claseprubart (DNTH103) in Generalized Myasthenia Gravis

Reuters
·
Sep 08, 2025

Dianthus Therapeutics Is Maintained at Outperform by Wedbush

Dow Jones
·
Aug 21, 2025

Wedbush Raises Price Target on Dianthus Therapeutics to $42 From $34, Keeps Outperform Rating

MT Newswires Live
·
Aug 21, 2025

Oncology Institute Inc: Richard Barasch Will Retire From His Role as Chairman

THOMSON REUTERS
·
Aug 14, 2025

the Oncology Institute Announces Changes to Board of Directors

THOMSON REUTERS
·
Aug 14, 2025

Stock Track | Dianthus Therapeutics Soars 5.11% as Evercore ISI Maintains Buy Rating

Stock Track
·
Aug 12, 2025